Designing cells to reduce immune rejection
Allogeneic cell therapies use donor cells. A recipient’s immune system can recognize and reject them. QUIET® applies Qihan’s genome editing platform to develop cells intended to provoke a weaker immune response.
Full platform nameQUiescent Immune Evasion Technology
Reducing immunogenicity
QUIET® studies how genetic edits affect the likelihood that the immune system will recognize and reject donor cells.
Evaluating designs in stages
Qihan evaluates candidate designs in cell-based and animal models before taking selected designs into clinical evaluation.
Protecting the underlying designs
Qihan reports a patent portfolio covering its underlying editing strategies in major global markets.
Research & development
From preclinical testing to clinical evaluation
Qihan reports that certain edits or combinations improved hypoimmunity in clinical evaluation. The company has incorporated some of these designs into clinical-stage products.
- Preclinical validation stages: cells, mice and nonhuman primates
- 3
- Patent coverage across major markets
- Global
